The molecular adsorbent recirculating system in posthepatectomy liver failure: Results from a prospective phase I study

Stefan Gilg, Ernesto Sparrelid, Lars Saraste, Greg Nowak, Staffan Wahlin, Cecilia Strömberg, Lars Lundell, Bengt Isaksson – 8 March 2018 – Posthepatectomy liver failure (PHLF) represents the single most important cause of postoperative mortality after major liver resection, yet no effective treatment option is available. Extracorporeal liver support devices might be helpful, but systematic studies are lacking. Accordingly, we aimed to assess the safety and feasibility of the Molecular Adsorbent Recirculating System (MARS) in patients with PHLF.

LiverLearning®: 2018 Webinar: Surgical Risk in the Portal Hypertensive Patient

The webinar will focus on the best practices and the underlying evidence in terms of surgical management of the portal hypertensive patient. A practical approach will be outlined whereby patient risk, assessment, and management will be discussed. This is an essential and daily part  of practice for hepatologists and this  webinar will update and educate as to current management.Brett E. Fortune (Moderator) Brett E. Fortune, MD, MSc, is a transplant hepatologist who works at New York Presbyterian/Weill Cornell for the Center for Liver Disease and Transplantation. Dr.

Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment

Margo J.H. van Campenhout, Florian van Bömmel, Maria Pfefferkorn, Janett Fischer, Danilo Deichsel, André Boonstra, Anneke J. van Vuuren, Thomas Berg, Bettina E. Hansen, Harry L.A. Janssen – 7 March 2018 – Hepatitis B virus (HBV) RNA in serum is a novel biomarker for intrahepatic HBV replication and treatment response. For its proper use, it is essential to identify factors influencing serum HBV RNA level.

Liver transplantation for intrahepatic cholangiocarcinoma

David D. Lee, Kristopher P. Croome, Kaitlyn R. Musto, Jose Melendez, Ghassan Tranesh, Raouf Nakhleh, C. Burcin Taner, Justin H. Nguyen, Tushar Patel, Denise M. Harnois – 7 March 2018 – Although hepatocellular carcinoma (HCC) has become a common indication for liver transplantation (LT), intrahepatic cholangiocarcinoma (ICC) and combined hepatocellular carcinoma–cholangiocarcinoma (cHCC‐CCA) are historically contraindicated due to their aggressive behavior.

Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet‐induced mouse model of nonalcoholic steatohepatitis

Annie J. Kruger, Bryan C. Fuchs, Ricard Masia, Jacinta A. Holmes, Shadi Salloum, Mozhdeh Sojoodi, Diego S. Ferreira, Stephanie M. Rutledge, Peter Caravan, Nadia Alatrakchi, Pam Vig, Eric Lefebvre, Raymond T. Chung – 7 March 2018 – Nonalcoholic steatohepatitis (NASH) is a progressive liver disease projected to become the leading cause of cirrhosis and liver transplantation in the next decade. Cenicriviroc (CVC), a dual chemokine receptor 2 and 5 antagonist, prevents macrophage trafficking and is under clinical investigation for the treatment of human NASH fibrosis.

Subscribe to